Eyepoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report released on Wednesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $47.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. Royal Bank Of Canada lowered their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Chardan Capital raised their price target on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Guggenheim restated a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.29.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $14.01 on Wednesday. The company has a market capitalization of $1.17 billion, a P/E ratio of -4.00 and a beta of 1.73. The company’s 50-day simple moving average is $13.18 and its two-hundred day simple moving average is $14.42. Eyepoint Pharmaceuticals has a one year low of $9.40 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.35 million. On average, research analysts expect that Eyepoint Pharmaceuticals will post -3.09 EPS for the current fiscal year.

Insider Transactions at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Cyndeo Wealth Partners LLC grew its holdings in Eyepoint Pharmaceuticals by 3.4% in the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock worth $420,000 after purchasing an additional 760 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares during the last quarter. RWC Asset Management LLP boosted its position in shares of Eyepoint Pharmaceuticals by 6.4% in the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares in the last quarter. MCF Advisors LLC boosted its position in shares of Eyepoint Pharmaceuticals by 8.3% in the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after purchasing an additional 1,149 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after buying an additional 1,177 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.